Chiwuzo Ife Okwumabua – Trademark Portfolio

Entity Type: 01

Chiwuzo Ife Okwumabua holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 1 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include CHI IFE. The owner is based in Atlanta, GA.

P.O. Box 77971

Atlanta, GA 30357

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

CHI IFE
CHI IFE
Registered 2020

Trademark Classifications

Chiwuzo Ife Okwumabua's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (1 filing)

Education; providing of training; entertainment; sporting and cultural activities

44
Medical Services (1 filing)

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Frequently Asked Questions

How many trademarks does Chiwuzo Ife Okwumabua have?

Chiwuzo Ife Okwumabua has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Chiwuzo Ife Okwumabua file in?

Chiwuzo Ife Okwumabua files trademarks across 2 Nice Classification classes. The most active classes are Class 41 (Education & Entertainment), Class 44 (Medical Services). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are Chiwuzo Ife Okwumabua's most well-known trademarks?

Chiwuzo Ife Okwumabua's registered trademark portfolio includes well-known marks such as CHI IFE. These are among 1 currently registered trademark in the portfolio.

What is Chiwuzo Ife Okwumabua's trademark registration success rate?

Chiwuzo Ife Okwumabua has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.